Navigation Links
Adoption of Minimally Invasive Prostate Cancer Treatment Options Slow
Date:6/25/2008

Chemotherapy and Cryosurgery are underused prostate cancer treatments in

the US, according to Millennium Research Group

WALTHAM, Mass., June 25 /PRNewswire/ -- Millennium Research Group (MRG) conducted a detailed survey of over 140 US and European based urologists during the recent 2008 American Urological Association (AUA) Annual Meeting. Results of this study are analyzed in the US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report. Data from the study suggests that several minimally invasive prostate cancer treatment options are underused in both the US and Europe.

US urologists indicated that cryosurgery was underused, while European urologists felt that both cryosurgery and high-intensity focused ultrasound (HIFU) were underused. In both regions, insufficient data supporting the treatments and the need to refer patients to another specialist were considered the leading barriers to adoption.

"These barriers will need to be addressed before utilization rates can increase notably," says Barbara Prud'homme, Senior Analyst at Millennium Research Group. "Expensive equipment, poor results with early cryosurgery equipment, and physician familiarity with traditional treatments such as radical prostatectomy, have deterred many from performing these minimally invasive procedures. Moreover, many urologists see cryosurgery as a salvage operation after other treatments haven't worked. One positive sign for the adoption of these treatments is that US and European urologists indicated that their use of these treatments had increased over the past year."

Although urologists were underusing new minimally invasive treatments, they were aware of emerging treatment options, including gene therapy and autoimmune therapy. Urologists believed emerging treatments would eventually improve patient outcomes.

MRG's US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report examines urologists' opinions on some of the industry's most discussed technologies, including permanent implant brachytherapy, high dose rate (HDR) brachytherapy, cryotherapy, and HIFU.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cincinnati Adoption Agency Invited to Participate in Values Voter Presidential Debate
2. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
3. Award recognizes 2 decades of research that led to the adoption of risk adjustment tools
4. MedeFile Applauds U.S. Presidential Hopefuls for Advocating Widespread Adoption of Electronic Medical Records
5. The University of California at San Francisco Medical Center Pioneers System-wide Adoption of Masimo Rainbow SET Technology
6. New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies
7. Gladney Center for Adoption Receives Whole Health Grant from Aetna Foundation
8. The Gladney Center for Adoption Names Mark L. Melson as Executive Vice President/Chief Development Officer
9. Minimally Invasive Heart Surgery Research Wins N.I.H. Award
10. Novadaq launches PINPOINT: Companys first minimally invasive imaging system
11. Published Results Using AtriCure Minimally Invasive Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God ... is the creation of published author, Stephen Miller, who, for over ten long years has ... to him. Born in Trinidad and Tobago, he has been serving the Lord for over ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter of 2016 on Wednesday, February 15, 2017, after ... ... on Wednesday, February 15, 2017, during which management will discuss the ... activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: